A blueprint for translational regenerative medicine

James P.K. Armstrong; Timothy Keane; Anne C. Roques; P. Stephen  Patrick; Claire M. Mooney; Wei-Li Kuan; Venkat Pisupati; Richard O. C. Oreffo; Daniel Stuckey; Fiona M Watt; Stuart Forbes; Roger A Barker; Molly M Stevens

doi:10.1126/scitranslmed.aaz2253

A blueprint for translational regenerative medicine

James P.K. Armstrong, Timothy Keane, Anne C. Roques, P. Stephen Patrick, Claire M. Mooney, Wei-Li Kuan, Venkat Pisupati, Richard O. C. Oreffo, Daniel Stuckey, Fiona M Watt, Stuart Forbes, Roger A Barker, Molly M Stevens

Research output: Contribution to journal › Article › peer-review

Abstract

The past few decades have produced a large number of proof-of-concept studies in regenerative medicine. However, the route to clinical adoption is fraught with technical and translational obstacles that frequently consign promising academic solutions to the so-called “valley of death.” Here, we present a proposed blueprint for translational regenerative medicine. We offer principles to help guide the selection of cells and materials, present key in vivo imaging modalities, and argue that the host immune response should be considered throughout design and development. Last, we suggest a pathway to navigate the often complex regulatory and manufacturing landscape of translational regenerative medicine.

Original language	English
Article number	eaaz2253
Number of pages	10
Journal	Science Translational Medicine
Volume	12
Issue number	572
DOIs	https://doi.org/10.1126/scitranslmed.aaz2253
Publication status	Published - 2 Dec 2020

Keywords / Materials (for Non-textual outputs)

regenerative medicine
tissue engineering
cells
biomaterials
translation

Access to Document

10.1126/scitranslmed.aaz2253

AAM - Stuart Forbes -A Blueprint for Translational Regenerative Medicine_Revised_Accepted_WithFiguresAccepted author manuscript, 1.21 MBLicence: Creative Commons: Attribution Non-Commercial (CC-BY-NC)

Cite this

@article{637f995918c24729ac92843a22837a59,

title = "A blueprint for translational regenerative medicine",

abstract = "The past few decades have produced a large number of proof-of-concept studies in regenerative medicine. However, the route to clinical adoption is fraught with technical and translational obstacles that frequently consign promising academic solutions to the so-called “valley of death.” Here, we present a proposed blueprint for translational regenerative medicine. We offer principles to help guide the selection of cells and materials, present key in vivo imaging modalities, and argue that the host immune response should be considered throughout design and development. Last, we suggest a pathway to navigate the often complex regulatory and manufacturing landscape of translational regenerative medicine.",

keywords = "regenerative medicine, tissue engineering, cells, biomaterials, translation",

author = "Armstrong, {James P.K.} and Timothy Keane and Roques, {Anne C.} and Patrick, {P. Stephen} and Mooney, {Claire M.} and Wei-Li Kuan and Venkat Pisupati and Oreffo, {Richard O. C.} and Daniel Stuckey and Watt, {Fiona M} and Stuart Forbes and Barker, {Roger A} and Stevens, {Molly M}",

year = "2020",

month = dec,

day = "2",

doi = "10.1126/scitranslmed.aaz2253",

language = "English",

volume = "12",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "572",

}

TY - JOUR

T1 - A blueprint for translational regenerative medicine

AU - Armstrong, James P.K.

AU - Keane, Timothy

AU - Roques, Anne C.

AU - Patrick, P. Stephen

AU - Mooney, Claire M.

AU - Kuan, Wei-Li

AU - Pisupati, Venkat

AU - Oreffo, Richard O. C.

AU - Stuckey, Daniel

AU - Watt, Fiona M

AU - Forbes, Stuart

AU - Barker, Roger A

AU - Stevens, Molly M

PY - 2020/12/2

Y1 - 2020/12/2

N2 - The past few decades have produced a large number of proof-of-concept studies in regenerative medicine. However, the route to clinical adoption is fraught with technical and translational obstacles that frequently consign promising academic solutions to the so-called “valley of death.” Here, we present a proposed blueprint for translational regenerative medicine. We offer principles to help guide the selection of cells and materials, present key in vivo imaging modalities, and argue that the host immune response should be considered throughout design and development. Last, we suggest a pathway to navigate the often complex regulatory and manufacturing landscape of translational regenerative medicine.

AB - The past few decades have produced a large number of proof-of-concept studies in regenerative medicine. However, the route to clinical adoption is fraught with technical and translational obstacles that frequently consign promising academic solutions to the so-called “valley of death.” Here, we present a proposed blueprint for translational regenerative medicine. We offer principles to help guide the selection of cells and materials, present key in vivo imaging modalities, and argue that the host immune response should be considered throughout design and development. Last, we suggest a pathway to navigate the often complex regulatory and manufacturing landscape of translational regenerative medicine.

KW - regenerative medicine

KW - tissue engineering

KW - cells

KW - biomaterials

KW - translation

U2 - 10.1126/scitranslmed.aaz2253

DO - 10.1126/scitranslmed.aaz2253

M3 - Article

SN - 1946-6234

VL - 12

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 572

M1 - eaaz2253

ER -

A blueprint for translational regenerative medicine

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this